BR112012003808A2 - modificação de adenovírus recombinante com epítopos de proteína de circunsporozoíto de plasmodium imunogênicos. - Google Patents
modificação de adenovírus recombinante com epítopos de proteína de circunsporozoíto de plasmodium imunogênicos.Info
- Publication number
- BR112012003808A2 BR112012003808A2 BR112012003808A BR112012003808A BR112012003808A2 BR 112012003808 A2 BR112012003808 A2 BR 112012003808A2 BR 112012003808 A BR112012003808 A BR 112012003808A BR 112012003808 A BR112012003808 A BR 112012003808A BR 112012003808 A2 BR112012003808 A2 BR 112012003808A2
- Authority
- BR
- Brazil
- Prior art keywords
- recombinant adenovirus
- protein
- plasmodium circumsporozoite
- modification
- directed
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title abstract 7
- 108700005482 Protozoan circumsporozoite Proteins 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 229940124735 malaria vaccine Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000013600 plasmid vector Substances 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 102000007999 Nuclear Proteins Human genes 0.000 abstract 1
- 108010089610 Nuclear Proteins Proteins 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 230000003263 anti-adenoviral effect Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000009145 protein modification Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2009/054212 WO2011022002A1 (en) | 2009-08-18 | 2009-08-18 | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
| PCT/US2010/045952 WO2011022522A1 (en) | 2009-08-18 | 2010-08-18 | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012003808A2 true BR112012003808A2 (pt) | 2016-11-16 |
Family
ID=43607237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012003808A BR112012003808A2 (pt) | 2009-08-18 | 2010-08-18 | modificação de adenovírus recombinante com epítopos de proteína de circunsporozoíto de plasmodium imunogênicos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170348405A1 (OSRAM) |
| EP (2) | EP3412306A3 (OSRAM) |
| JP (2) | JP5947719B2 (OSRAM) |
| KR (1) | KR20120094469A (OSRAM) |
| CN (2) | CN103025349B (OSRAM) |
| BR (1) | BR112012003808A2 (OSRAM) |
| CA (1) | CA2769415A1 (OSRAM) |
| IL (1) | IL217709A (OSRAM) |
| MX (1) | MX339830B (OSRAM) |
| NZ (1) | NZ598703A (OSRAM) |
| PH (1) | PH12012500164A1 (OSRAM) |
| RU (1) | RU2585228C2 (OSRAM) |
| SG (2) | SG10201404970PA (OSRAM) |
| UA (1) | UA108081C2 (OSRAM) |
| WO (2) | WO2011022002A1 (OSRAM) |
| ZA (1) | ZA201201286B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9115205B2 (en) | 2010-10-18 | 2015-08-25 | The United States Of America, As Represented By The Secretary Of The Army | Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression |
| US20120244178A1 (en) * | 2011-03-25 | 2012-09-27 | Denise Doolan | Plasmodium falciparum antigens |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| CN105431535A (zh) * | 2013-06-03 | 2016-03-23 | Vlp治疗有限责任公司 | 疟疾疫苗 |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| US9968665B2 (en) * | 2015-09-16 | 2018-05-15 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
| LT3405582T (lt) * | 2016-01-21 | 2020-12-10 | Janssen Vaccines & Prevention B.V. | Patobulinta vakciną nuo maliarijos adenoviruso, koduojančio ir eksponuojančio maliarijos antigeną, pagrindu |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| CN107841513B (zh) * | 2016-09-18 | 2023-04-14 | 中国科学院上海巴斯德研究所 | 基于M2e表位的广谱型流感疫苗 |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN108192876A (zh) * | 2017-12-07 | 2018-06-22 | 东莞市第八人民医院 | 一种人3型腺病毒衣壳蛋白同时展示ca16双中和抗原表位疫苗候选株的制备方法和应用 |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| WO2020221451A1 (en) * | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Antibodies binding to plasmodium circumsporozoite protein and uses thereof |
| CN110687289B (zh) * | 2019-10-17 | 2023-04-18 | 中国人民解放军陆军军医大学 | Fgl2蛋白作为疟疾感染标志物的应用 |
| GB201915905D0 (en) * | 2019-11-01 | 2019-12-18 | Spybiotech Ltd | Viruses with modified capsid proteins |
| JP2021178021A (ja) * | 2020-05-14 | 2021-11-18 | 株式会社三洋物産 | 遊技機 |
| US20240240203A1 (en) * | 2021-05-04 | 2024-07-18 | SpyBiotech Limited | Adenoviral vectors and vaccines thereof |
| AU2022349649A1 (en) * | 2021-09-23 | 2024-04-04 | Sagittarius Bio, Inc. | Adenoviruses and methods for using adenoviruses |
| CN120944926B (zh) * | 2025-10-15 | 2026-01-30 | 华中科技大学同济医学院附属同济医院 | 衣壳表面展示超大片段抗原的重组腺病毒、构建方法及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6066623A (en) * | 1993-11-23 | 2000-05-23 | The United States Of America As Represented By The Secretary Of The Navy | Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines |
| JP2005500336A (ja) * | 2001-07-25 | 2005-01-06 | ニューヨーク・ユニバーシティ | 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用 |
| EP2277533B1 (en) * | 2002-10-23 | 2016-07-20 | GlaxoSmithKline Biologicals S.A. | Methods for vaccinating against malaria |
| WO2004055187A1 (en) * | 2002-12-17 | 2004-07-01 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| AU2004238979B2 (en) * | 2003-05-14 | 2008-12-18 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Broadening adenovirus tropism |
| JP2005287309A (ja) * | 2004-03-31 | 2005-10-20 | Dnavec Research Inc | 遺伝子導入を増強するための薬剤および方法 |
| ES2358523T3 (es) * | 2004-10-13 | 2011-05-11 | Crucell Holland B.V. | Vectores adenovirales mejorados y usos de los mismos. |
| AU2006284756B2 (en) * | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2008140474A1 (en) * | 2006-10-26 | 2008-11-20 | Johns Hopkins University | Recombinant adenovirus vaccines |
-
2009
- 2009-08-18 WO PCT/US2009/054212 patent/WO2011022002A1/en not_active Ceased
-
2010
- 2010-08-18 CA CA2769415A patent/CA2769415A1/en not_active Abandoned
- 2010-08-18 MX MX2012002131A patent/MX339830B/es active IP Right Grant
- 2010-08-18 KR KR1020127006889A patent/KR20120094469A/ko not_active Ceased
- 2010-08-18 PH PH1/2012/500164A patent/PH12012500164A1/en unknown
- 2010-08-18 CN CN201080047059.6A patent/CN103025349B/zh not_active Expired - Fee Related
- 2010-08-18 JP JP2012525677A patent/JP5947719B2/ja not_active Expired - Fee Related
- 2010-08-18 UA UAA201203125A patent/UA108081C2/ru unknown
- 2010-08-18 EP EP18168155.2A patent/EP3412306A3/en not_active Withdrawn
- 2010-08-18 CN CN201510745347.3A patent/CN105770880A/zh active Pending
- 2010-08-18 RU RU2012110255/10A patent/RU2585228C2/ru not_active IP Right Cessation
- 2010-08-18 NZ NZ598703A patent/NZ598703A/en not_active IP Right Cessation
- 2010-08-18 EP EP10810576.8A patent/EP2467157A4/en not_active Withdrawn
- 2010-08-18 SG SG10201404970PA patent/SG10201404970PA/en unknown
- 2010-08-18 SG SG2012011144A patent/SG178476A1/en unknown
- 2010-08-18 BR BR112012003808A patent/BR112012003808A2/pt not_active IP Right Cessation
- 2010-08-18 WO PCT/US2010/045952 patent/WO2011022522A1/en not_active Ceased
-
2012
- 2012-01-24 IL IL217709A patent/IL217709A/en not_active IP Right Cessation
- 2012-02-21 ZA ZA2012/01286A patent/ZA201201286B/en unknown
-
2016
- 2016-03-03 JP JP2016041230A patent/JP6293181B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-30 US US15/419,523 patent/US20170348405A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170348405A1 (en) | 2017-12-07 |
| EP2467157A4 (en) | 2014-01-22 |
| MX2012002131A (es) | 2012-04-11 |
| EP3412306A3 (en) | 2019-01-02 |
| EP3412306A2 (en) | 2018-12-12 |
| JP2013502221A (ja) | 2013-01-24 |
| IL217709A0 (en) | 2012-03-29 |
| NZ598703A (en) | 2014-04-30 |
| WO2011022522A1 (en) | 2011-02-24 |
| JP2016146837A (ja) | 2016-08-18 |
| CA2769415A1 (en) | 2011-02-24 |
| CN103025349A (zh) | 2013-04-03 |
| HK1179508A1 (zh) | 2013-10-04 |
| ZA201201286B (en) | 2013-05-29 |
| SG178476A1 (en) | 2012-03-29 |
| PH12012500164A1 (en) | 2022-03-09 |
| AU2010286187A1 (en) | 2012-02-16 |
| UA108081C2 (uk) | 2015-03-25 |
| MX339830B (es) | 2016-06-13 |
| CN105770880A (zh) | 2016-07-20 |
| EP2467157A1 (en) | 2012-06-27 |
| IL217709A (en) | 2016-05-31 |
| CN103025349B (zh) | 2016-05-18 |
| JP5947719B2 (ja) | 2016-07-06 |
| SG10201404970PA (en) | 2014-10-30 |
| WO2011022002A1 (en) | 2011-02-24 |
| RU2012110255A (ru) | 2013-09-27 |
| KR20120094469A (ko) | 2012-08-24 |
| JP6293181B2 (ja) | 2018-03-14 |
| RU2585228C2 (ru) | 2016-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012500164A1 (en) | Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes | |
| BR112018012962A2 (pt) | vacinas de zika recombinantes | |
| BRPI0821286A8 (pt) | Métodos e composições para imunizar porcos contra circovirus suino | |
| EA201170812A1 (ru) | Способы и композиции для применения вакцины против кокцидиоза | |
| JP2017530124A5 (OSRAM) | ||
| MX355366B (es) | Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. | |
| WO2011112945A3 (en) | Foot and mouth disease virus recombinant vaccines and uses thereof | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2014530003A5 (OSRAM) | ||
| BR112014020019A2 (pt) | vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes | |
| PH12019500592A1 (en) | New swine influenza vaccine | |
| BR112012031211A2 (pt) | métodos e vacina para reduzir a infecção causada pelo campylobacter | |
| AR105482A1 (es) | Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso | |
| SI2538972T1 (en) | Recombinant CDV compositions and their uses | |
| MY207126A (en) | 4/91 ibv vaccine with heterologous spike protein | |
| BRPI0813313A8 (pt) | Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv. | |
| MY206043A (en) | H52 ibv vaccine with heterologous spike protein | |
| BRPI0904020B8 (pt) | composição vacinal contra o vírus da dengue, e, kit | |
| BR112017013270A2 (pt) | ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?. | |
| BR112014023283A8 (pt) | Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza | |
| WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same | |
| TN2014000393A1 (en) | Modified marek's disease virus, and vaccines made therefrom | |
| BR112012004703A2 (pt) | regime de imunização inicial de reforço heterólogo contra o vírus da língua azul. | |
| CN107841513A (zh) | 基于M2e表位的广谱型流感疫苗 | |
| MX2016002399A (es) | Virus recombinante de la enfermedad de newcastle que expresa una proteina inmunomoduladora como adyuvante molecular. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2475 DE 12-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |